Skip to main content

Advertisement

We're creating a new version of this page. See preview

  • Research note
  • Open Access

Quality of life of Moroccan patients on the palliative phase of advanced cancer

  • 1, 2Email author,
  • 1, 2,
  • 3,
  • 4 and
  • 1, 2
BMC Research Notes201912:351

https://doi.org/10.1186/s13104-019-4390-1

  • Received: 24 February 2019
  • Accepted: 14 June 2019
  • Published:

Abstract

Objective

The aim of this study is to assess the quality of life of caregiver’s. The study was conducted at the RABAT National Institute of Oncology in MOROCCO.

Results

120 patients on the palliative phase of advanced cancer were included. Severe fatigue was observed in 64.2% of patients with an average of 90.55 ± 14.7. There was a positive association between functional dimensions and overall quality of life and a negative association between symptoms and overall quality of life. Patients under 30 years had a lower quality of life. According to the multi-varied analysis, physical function, emotional functioning and fatigue were significant predictors of Health related quality of life/overall quality of life (p < 0.05).

Keywords

  • Advanced cancer
  • Quality of life
  • Palliative phase
  • QLQ-C15-PAL

Introduction

Nowadays, for many patients, the palliative phase is not equal to the terminal phase, but to a treatment phase, in which the intention is to prolong the patient’s life and/or relieve symptoms, transforming advanced cancer into a chronic disease [1]. On the other hand, when metastases have developed and cancer is in all likelihood incurable, patients find themselves in a situation of psychological fragility due to the existential threat now realized, regardless of their individual prognosis [2]. They experienced situations of hope, uncertainty, disappointment, exhaustion and, most of the time, physical deterioration [3].

Patients with advanced palliative cancer suffer from various symptoms [4]. The most distressing are Fatigue, pain and anxiety, others considered common, including lack of appetite, dyspnea, constipation and nausea [5]. Patients with advanced palliative phase cancer have a poor quality of life regardless of the type of cancer [4, 6].

Frequent occurrence of symptoms has been shown to have a significant impact on patient satisfaction with health-related quality of life (HRQoL) [710].

HRQoL has been defined as a state of well-being that is based on components: the ability to perform daily activities that reflect physical, psychological and social well-being; patient satisfaction with their level of functioning, control of their illness and symptoms related to their treatment [11, 12].

QoL assessment is structured around at least three dimensions, which are the physical, psychological and social domains [11, 13]. For other teams, an assessment of quality of life must be based on an additional field, symptomatology, thus allowing an assessment of quality of life in at least four dimensions [14, 15].

It is necessary to consider the particular context of advanced palliative cancer patients, including physical impairment, loss of autonomy, pain, anxiety, anger, time, feeling of being a burden, relationships with others [16].

In the lung cancer literature, this concept was explored using the EORTC QLQ-C30 questionnaire to study the relative importance of the various symptoms and functional domains of health-related quality of life in predicting overall QOL [17, 18].

Patients with advanced, palliative or terminal cancer are a sensitive, vulnerable population that requires special attention.

For that an abbreviated version of the QLQ-C30, known as QLQ-C15-PAL, was developed to reduce the burden of the longer and more cumbersome questionnaire to be completed by patients with advanced palliative cancer to assess their quality of life [19].

Several studies have shown a deteriorated quality of life of patients with advanced cancer in the palliative phase [16]. But in Morocco no study is interested in the quality of life of this category of patients.

The main objective of this study is to evaluate the quality of life of Moroccan patients with advanced palliative cancer.

The results of our study will highlight the difficulties experienced by this population to enable them to benefit from global and integrated care.

Main text

Methods

Instruments and procedures

Information about patient characteristics: age, sex, cancer location, stage, metastasis, duration of palliative phase, marital status, employment status and treatment received, were collected from medical records. GHS and QoL were assessed using QLQ-C15-PAL, it is a questionnaire that has been developed specifically for use in palliative care settings through validation studies [2022]. This QOL measurement tool includes 15 questions; two multi-element functional scales (physical and emotional functioning), two multi-element symptomatic scales (fatigue and pain) as well as five single-element symptomatic scales (nausea/vomiting, dyspnoea, insomnia, loss of appetite, constipation) and a final question concerning general QOL.

In order to generate the scores of the different scales of the QLQ-C15-PAL, the EORTC QLQ-C30 scoring manual [23] and the QLQ-C15-PAL addendum [24] were used. Scores are defined on a scale from 0 to 100. Scores close to 100 for the symptom scale represent a high symptom load. A high score for both functional scales and the last question of the QLQ-C15-PAL, which refers to the patient’s perception of the overall QOL; represents a positive response.

The EORTC QLQ-C- 15 PAL questionnaire was translated into Moroccan dialectal Arabic, adapted and validated for Moroccan context [25].

To assess the patient’s clinical condition, the Karnofsky Performance Scale was used.

The subjects recruitment

The EORTC QLQ-C-15 questionnaire was administered to patients with advanced stage cancer reported in the palliative phase and not receiving chemotherapy or palliative radiotherapy who were hospitalized in the oncology and palliative care departments at the National Institute of Oncology (INO) SIDI MOHAMED IBN ABDILLAH in RABAT/MOROCCO; first reference centre in cancer treatment in Morocco.

Were included in the study, patients diagnosed with histological confirmed cancer and in palliative phase who were hospitalized in the above-mentioned services, patients of Moroccan nationality and who had signed an informed consent letter to participate in the study. Exclusion criteria are patients with psychiatric or neurological disorders that may impair understanding and adherence to the study.

Using the medical records, we identified the cancer patients who met the criteria and recruited them to participate in the study from December 2017 to July 2018.

Statistical analysis

A descriptive analysis of the socio-demographic and clinical characteristics was carried out. We calculated means, standard deviations, minimum and maximum values. The ANOVA test was used to analyze differences in scores between sex, age groups and duration of palliative care and also to compare the average scores of the different scales to a classification of patient groups using the KPS.

Pearson correlations were calculated between all functional/symptom scales and the global scale of quality of life. A simple linear regression model was applied to detect the association between Q15 (global QOL) and functional and symptomatic dimension scores. Significant variables from the univariate analysis (p < 0.05) were introduced into the multivariate analysis.

The tests were considered significant when the p (degree of significance) was less than 0.05. The statistical analysis is performed using the SPSS version software 13.0.

Results

Out of a total of 120 patients included in the study, 57.5% were female and 54% were illiterate. Participants were aged 20 to 92 years. The most frequent primary cancer diagnoses were respectively (43% gynaecological and mammary, 37.5% digestive, 22% pulmonary). 65.9% of patients had a Karnovsky index between 40 and 50% and the average duration of palliative phase was 22.89 months with extremes [1–204]. Other socio-demographic and clinical characteristics are presented in (Table 1).
Table 1

Characteristics of patient and diseases (N = 120)

 

Characteristics

N

%

Age(years)

Age (mean ± SD)

120

59 ± 16.5

Gender

Female

69

57.5

Male

51

42.5

Residence

Urban

93

77.5

Rural

27

22.3

Marital status

Married

94

78.3

Widower

12

10

Single

14

11.6

Level of education

Illiterate

54

45

Primary school

36

30

Secondary school

28

23.4

University

1

0.8

Employment status

Unemployed

76

73.3

Employed

44

36.7

Social security coverage

RAMED

100

83.3

AMO

19

15.8

Primary cancer diagnosis

Lung

22

18.3

Digestive

45

37.5

Gynecological and Breast

43

35.8

Uro

5

4.2

Others

5

4.2

Treatment received

Yes

99

82.5

No

21

17.5

Clinical stage

M0

51

42.5

M1

15

12.5

NP

54

45

Karnofsky index

≤ 30

31

25.8

[40–50]

79

65.9

≥ 60

10

8.4

Period of transition to palliative phase (months/mean)

 

22.89

 

AMO: insurance for public sector employees; RAMED: insurance for economically weak patients

A poor overall quality of life was reported in 32.5% of patients with an average of (24.44 ± 21.27), 46.7% of patients found their functioning extremely impaired (15.46 ± 17.18). 28.3% of participants reported that they had no problems with the emotional component and 34.2% made this component responsible for an extreme problem in their daily lives with an average score of 50.13 ± 42.03.

In our study population, 64.2% showed fatigue with an average of 90.55 ± 14.7, 20% experienced nausea/vomiting (43.88 ± 36.15), 20% experienced pain (74.30 ± 19.79), 25% experienced dyspnoea (50.55 ± 35.63), 32.5% had insomnia (68.05 ± 26.77), 58.3% lost appetite (80.83 ± 25.07), 20.8% experienced constipation (36.94 ± 39.08) (Table 2).
Table 2

Quality of life; functional and symptomatic scales (n = 120)

 

Mean

SD

Minimum

Maximum

Functional scales

 Physical functioning

15.46

17.18

00

55.56

 Emotional functioning

50.13

42.03

00

100

Symptom scales

 Fatigue

90.55

14.77

33.33

100

 Nausea and vomiting

43.88

36.15

00

100

 Pain

74.30

19.79

00

100

 Dyspnoea

50.55

35.63

00

100

 Insomnia

68.05

26.77

00

100

 Appetite loss

80.83

25.07

33.33

100

 Constipation

36.94

39.08

00

100

 Global health status/quality of life

24.44

21.27

00

66.67

CI, confidence interval, PF physical functioning, PE emotional functioning, FA fatigue, NV nausea and vomiting, PA pain

That results showed that women have experienced dyspnoea with a p value < 0.05. There is significant variation in the age of patients, the lowest estimate of health status being for patients under 30 years of age. The emotional functional scale is significantly associated with the age of patients. Elderly subjects (> 70 years of age) were more sensitive to the symptom of pain. Symptoms (NV) and (AP) are significantly and significantly associated with the duration of the disease. KPS is significantly related to the physical functional scale of fatigue, loss of appetite (Additional file 1: Table S1).

Correlations were significant between Q15 (GHS/QOL) and functional scales with a positive score and between Q15 and symptom scale with a negative score; with the exception of constipation (Additional file 1: Table S2).

Based on QLQ-C15-PAL dimensions; in the univariate analysis, the overall QOL (Q15) shows a positive coefficient with respect to physical and emotional functioning (p < 0.05) and a negative coefficient for fatigue, pain, dyspnea, insomnia, loss of appetite (p < 0.05). According to the multi-varied analysis of QLQ-C15-PAL, physical function, emotional functioning and fatigue (p <0.05) were significant predictors of GHS/QOL (Q15) (Table 3).
Table 3

Univariate and multivariate linear regression analysis of all functional/Symptomatic scales with overall QOL in palliative cancer patients

Independent variable

Univariate analysis

Multivariate analysis

β

P value

β

[95.0% CI]

P value

PF

0.29

0.01

[0.021 to 0. 33]

0.17

0.02

PE

0.39

0.00

[0.32 to 0.45]

0.38

0.00

FA

− 0.66

0.00

[− 0.48 to − 0.09]

− 0.28

0.004

NV

− 0.06

0.24

   

PA

− 0.49

0.00

[− 0.12 to 0.17]

0.02

0.75

Dy

− 0.13

0.01

[− 0.14 to 0.009]

− 0.06

0.08

SL

− 0.26

0.00

[− 0.001 to 0.23]

0.11

0.052

AP

− 0.18

0.01

[− 0.13 to 0.05]

− 0.04

0.36

CO

0.003

0.95

   

Dy dyspnoea, Sl insomnia, AP appetite loss, CO constipation

Discussion

This study is the first in Morocco where elements reflecting QLQ-C15-PAL were extracted from the QLQ-C30 questionnaire translated into Moroccan dialectal Arabic and analyzed for their predictive coefficients to QOL.

The results describe the onset of symptoms and impaired functioning in patients with advanced palliative stage cancer. Significant deterioration was observed in all aspects of physical and emotional functioning, with fatigue, loss of appetite, insomnia and pain being the most common symptoms experienced by patients; nausea and vomiting were considered the least problematic. Men and women reported similar levels of problems, unlike other studies that showed clear gender differences, focusing on specific symptoms, which were observed mainly insomnia (more in men) and nausea and vomiting (more frequent in women) [2631]. Fatigue was more pronounced in all age groups in our study, similar to the results of a previous study [19]. It is known to be one of the most distressing symptoms for palliative cancer patients and negatively affects their daily lives [3240]; its prevalence rates can reach 99% in patients with advanced and incurable cancers [3437, 41].

Our results didn’t show differences between age groups for physical functioning, unlike other studies that showed divergent results. Indeed, The study conducted in a German population showed that physical functioning was lower in elderly subjects with higher scores for fatigue, nausea/vomiting, pain, dyspnoea, loss of appetite and constipation [42].

Overall, elderly subjects tended to report fewer problems than younger patients with more severe quality of life deterioration. Some studies have shown that older cancer patients have similar or even better HRQoL than younger patients [43]. Others have found that a lower overall HRQoL is associated with increased age, with different expectations for HRQoL in elderly patients [44].

Our results have shown, physical and emotional functioning were significant predictors of QOL, and with such a high burden of symptoms, it makes sense to identify the most important for the patient in terms of overall quality of life, so that palliative and supportive care can be adapted accordingly.

Study conducted at the National Cancer Institute of Canada showed that patients with low emotional functioning scores; have low overall quality of life scores [45].

Fatigue was the most common symptom in patients with advanced palliative cancer and can significantly worsen their QOL. Since it was the most significant predictive symptom in this study, our results are fully consistent with the results of other studies that have shown that fatigue was influenced by many factors (pain, nausea, depression, insomnia and dyspnoea) and had a significant association with general well-being [4547].

QLQ C 15-PAL is more effective and appropriate for measuring QOL in palliative cancer patients. It is recommended to initiate studies in Morocco using this assessment tool. The poor physical condition of palliative patients means that shorter quality of life questionnaires can help reduce burden and improve data accumulation, and appropriate assessment of quality of life in patients with advanced disease can guide targeted interventions by health personnel [48].

Conclusion

In our study, the majority of patients with advanced palliative cancer experienced a deteriorated quality of life related to the onset and persistence of certain symptoms, particularly fatigue, loss of appetite and insomnia. Emotional and physical functioning as well as fatigue was significant predictors of overall quality of life in palliative patients.

It is recommended that accurate quality of life assessments be conducted in palliative research. Care should be based on the intensity of symptoms, their burden and their impact on patients’ quality of life.

Limitations

Some limits must be taken into account: The QLQ C-15-PAL is a self-administered questionnaire, the problem of patient’s illiteracy, which has resulted in administration by the same investigator. Also, the short form of EORTC C 15-PAL is unable to evaluate some areas of QLQ-C-30.

Abbreviations

PF: 

physical functioning

PE: 

emotional functioning,

FA: 

fatigue

NV: 

nausea and vomiting

PA: 

pain

Dy: 

dyspnoea

SL: 

insomnia

AP: 

appetite loss

CO: 

constipation

GHS/QoL: 

global health status/quality of life

HDR: 

out of all therapeutic resources

CI: 

confidence interval

KPS: 

Karnofsky Performance Scale

Declarations

Acknowledgements

The authors thank the team of Mapi research for permitting the use of CarQoQoL. We also thank the staff at the National Oncology Institute in Rabat, Moroccofor this study. We thank Ms. Fouzia Hammouch, Dr. Laila Lahlou and professor Saber Boutayeb for their collaboration all along the completion of this study. We thank the patients and families for their cooperation.

Funding

There was no funding for this study.

Authors’ contributions

AA designed the study and analyzed the data and wrote the manuscript. BHR participated in the statistical analysis and was involved in the writing of the manuscript. RR contributed to the design, analysis, and interpretation of the data and was involved in the writing of the manuscript. EH and MH were critically involved in analysis, interpretation of data, the revision of the manuscript and gave final approval of the version to be published. All authors read and approved the final manuscript.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Ethics approval and consent to participate

All participants signed a written consent. The study has been approved by the ethics committee for biomedical research of the MOHAMED V Faculty of Medicine and Pharmacy in RABAT (N/R: Folder Number 15/18).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco
(2)
Translational Oncology Research Team, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco
(3)
Research Department, Higher Institute of Nursing Professions and Technical Health, Rabat, Morocco
(4)
Laboratory of Social Medicine and Public Health, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco

References

  1. Marlies EW, Martine MG, Tineke JS, et al. A prospective analysis on fatigue and experienced burden in informal caregivers of cancer patients during cancer treatment in the palliative phase. Acta Oncol. 2015;54(4):500–6. https://doi.org/10.3109/0284186x.2014.953254.View ArticleGoogle Scholar
  2. Gisèle CH, David P, Yves D, Laurence L, Paul R, et al. Étude prospective de qualité des soins et de qualité de vie chez des patients cancéreux en phase palliative, en hospitalisation ou à domicile: analyse intermédiaire de l’étude Trapado. Février. 2006;93:2.Google Scholar
  3. Markus B, Daniel R, et al. Chimiothérapie palliative ou plutôt soins palliatifs? Swis Medical Forum. In: Forum médicale Suisse. 2015. Vol. 15, No. 16, p. 334–39.Google Scholar
  4. Gilbertson WS, Aouizerat BE, Jahan T, Miaskowski C. A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer. Palliat Support Care. 2011;9:81–102.View ArticleGoogle Scholar
  5. van Lancker A, Velghe A, Hecke A, Verbrugghe M, van den Noortgate N, Grypdonck M, Verhaeghe S, Bekkering G, Beeckman D. Prevalence of symptoms in older cancer patients receiving palliative care: a systematic review and meta-analysis. J Pain Symptom Manag. 2014;47:90–104.View ArticleGoogle Scholar
  6. Strömgren AS, Sjogren P, Goldschmidt D, Petersen MA, Pedersen L, Hoermann L, Groenvold M. A longitudinal study of palliative care: patient-evaluated outcome and impact of attrition. Cancer. 2005;103:1747–55.View ArticleGoogle Scholar
  7. Feyer P, Kleeberg UR, Steingraber M, Gunther W, Behrens M. Frequency of side effects in outpatient cancer care and their influence on patient satisfaction–a prospective survey using the PASQOC questionnaire. Support Care Cancer. 2008;16(6):567–75.View ArticleGoogle Scholar
  8. Gupta D, Lis CG, Grutsch JF. The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage. 2007;34(1):40–7.View ArticleGoogle Scholar
  9. Lis CG, Gupta D, Grutsch JF. The relationship between insomnia and patient satisfaction with quality of life in cancer. Support Care Cancer. 2008;16(3):261–6.View ArticleGoogle Scholar
  10. Osoba D, Hsu MA, Copley MC, Coombs J, Johnson FR, Hauber B, et al. Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual Life Res. 2006;15(2):273–83.View ArticleGoogle Scholar
  11. Feld R. Endpoints in cancer clinical trials. Is there a need for measuring quality of life? Support Care Cancer. 1995;3(1):23–7.View ArticleGoogle Scholar
  12. Gotay CC, et al. Quality-of-life assessment in cancer treatment protocols Research issues in protocoldevelopment. J Natl Cancer Inst. 1992;84(8):575–9.View ArticleGoogle Scholar
  13. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 1999;2(2):113–27.View ArticleGoogle Scholar
  14. Wood DS. Assessing quality of life in clinical research: from where have we come and where are we going? J Clin Epidemiol. 1999;52(4):355–63.View ArticleGoogle Scholar
  15. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol. 1994;12(3):608–16.View ArticleGoogle Scholar
  16. Teno JM, Byock I, Field MJ. Research agenda for developing measures to examine quality of care and quality of life of patients diagnosed with life-limiting illness. J Pain Symptom Manage. 1999;17(2):75–82.View ArticleGoogle Scholar
  17. Cooley ME. Quality of life in persons with non-small cell lung cancer: a concept analysis. Cancer Nurs. 1998;21(3):151–61.View ArticleGoogle Scholar
  18. Ostlund U, Wennman LA, Gustavsson P, Wengstrom Y. What symptom and functional dimensions can be predictors for global ratings of overall quality of life in lung cancer patients? Support Care Cancer. 2007;15(10):1199–205.View ArticleGoogle Scholar
  19. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006;42(1):55–64.View ArticleGoogle Scholar
  20. Lien K, Zeng L, Nguyen J, et al. Comparison of the EORTC QLQ-C15-PAL and the FACIT-Pal for assessment of quality of life in patients with advanced cancer. Expert Rev Pharmacoecon Outcome Res. 2011;11:541–7.View ArticleGoogle Scholar
  21. Suarez-del-Real Y, Allende-Perez S, Alferez-Mancera A, et al. Validation of the Mexican-Spanish version of the EORTC QLQ-C15-PAL questionnaire for the evaluation of health-related quality of life in patients on palliative care. Psychooncology. 2011;20:889–96.View ArticleGoogle Scholar
  22. Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006;42:55–64.View ArticleGoogle Scholar
  23. Groenvold M, Petersen MA. Addendum to the EORTC QLQ-C30. Scoring manual. 2006: Scoring of the EORTC QLQ-C15-PAL).Google Scholar
  24. Fayers PM, Aaronson N, Bjordal K, et al. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer; 2001.Google Scholar
  25. Nejjari, et al. Translation and validation of European organization for research and treatment of cancer quality of life Questionnaire-C30 into Moroccan version for cancer patients in Morocco. BMC Res Notes. 2014;7:228.View ArticleGoogle Scholar
  26. Higginson IJ, Addington HJM. The epidemiology of death and symptoms Oxford textbook of palliative medicine. 3rd ed. Oxford: Oxford University Press; 2005. p. 14–24.Google Scholar
  27. Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage. 1994;9:372–82.View ArticleGoogle Scholar
  28. Lidstone V, Butters E, Seed PT, et al. Symptoms and concerns amongst cancer outpatients: identifying the need for specialist palliative care. Palliat Med. 2003;17:588–95.View ArticleGoogle Scholar
  29. Lo RS, Ding A, Chung TK, Woo J. Prospective study of symptom control in 133 cases of palliative care inpatients in Shatin Hospital. Palliat Med. 1999;13:335–40.View ArticleGoogle Scholar
  30. Krech RL, Davis J, Walsh D, Curtis EB. Symptoms of lung cancer. Palliat Med. 1992;6:309–15.View ArticleGoogle Scholar
  31. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer. 2000;8:175–9.View ArticleGoogle Scholar
  32. Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer-related fatigue: a critical appraisal. Eur J Cancer. 2006;42:846–63.View ArticleGoogle Scholar
  33. Yennurajalingam S, Palmer JL, Zhang T, Poulter V, Bruera E. Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Support Care Cancer. 2008;16(10):1125–30.View ArticleGoogle Scholar
  34. Hauser K, Walsh D, Rybicki LA, Davis MP, Seyidova KD. Fatigue in advanced cancer: a prospective study. Am J Hosp Palliat Care. 2008;25(5):372–8.View ArticleGoogle Scholar
  35. Stone PC, Minton O. Cancer-related fatigue. Eur J Cancer. 2008;44(8):1097–104.View ArticleGoogle Scholar
  36. Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients Van EAPC approach. Palliat Med. 2008;22:13–32.View ArticleGoogle Scholar
  37. Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007;34(1):94–104.View ArticleGoogle Scholar
  38. Higginson IJ, Costantini M. Dying with cancer, living well with advanced cancer. Eur J Cancer. 2008;44:1414–24.View ArticleGoogle Scholar
  39. Thompson GN, Chochinov HM, Wilson KG, et al. Prognostic acceptance and the well-being of patients receiving palliative care for cancer. J Clin Oncol. 2009;27(34):5757–62.View ArticleGoogle Scholar
  40. Siddiqi A, Given CW, Given B, Sikorskii A. Quality of life among patients with primary, metastatic and recurrent cancer. Eur J Cancer. 2009;18:84–96.View ArticleGoogle Scholar
  41. Butt Z, Rosenbloom SK, Abernethy AP, et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Cancer Netw. 2008;6(5):448–55.View ArticleGoogle Scholar
  42. Baumann R, Putz C, Rohrig B, Hoffken K, Wedding U. Health-related quality of life in elderly cancer patients, elderly non-cancer patients and an elderly general population. Eur J Cancer Care. 2009;18(5):457–65.View ArticleGoogle Scholar
  43. Zimmermann C, Burman D, Swami N, et al. Determinants of quality of life in patients with advanced cancer. Support Care Cancer. 2011;19:621–9.View ArticleGoogle Scholar
  44. Hjermstad MJ, Fayers PM, Bjordal K, et al. Using reference data on quality of life-the importance of adjusting age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer. 1998;34:1381–9.View ArticleGoogle Scholar
  45. Stone P, Hardy J, Broadley K, Tookman AJ, Kurowska A, Aern R. Fatigue in advanced cancer. a prospective con-trolled cross-sectional study. Br J Cancer. 1999;79:1479–86.View ArticleGoogle Scholar
  46. Zeng L, Koo K, Zhang L, et al. Fatigue in advanced cancer patients attending an outpatient palliative radiotherapy clinic as screened by the Edmonton Symptom Assessment System. Support Care Cancer. 2012;20:1037–42.View ArticleGoogle Scholar
  47. Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, et al. Quality of life scores; an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res. 1997;6:151–8.View ArticleGoogle Scholar
  48. Arraras JI, de la Vega FA, Asin G, et al. The EORTC QLQ–C15–PAL questionnaire: validation study for Spanish bone metastases patients. Qual Life Res. 2014;23(3):849–55.View ArticleGoogle Scholar
  49. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: McLeod CM, editor. evaluation of chemotherapeutic agents. New York: Columbia University Press; 1948. p. 199–205.Google Scholar
  50. Whoqol Group. Study protocol for the World Health Organisation project to develop a quality of life assessment instrument (Whoqol). Qual Lif Res. 1993;2:153–9.View ArticleGoogle Scholar

Copyright

© The Author(s) 2019

Advertisement